Intraoperative radiation therapy in uterine cervical cancer: A review by Biete, Albert & Oses, Gabriela
reports of practical oncology and radiotherapy 2 3 ( 2 0 1 8 ) 589–594
Available online at www.sciencedirect.com
ScienceDirect
journa l homepage: ht tp : / /www.e lsev ier .com/ locate / rpor
Review
Intraoperative radiation therapy in uterine cervical
cancer: A review
Albert Bietea,b,∗, Gabriela Osesa
a Radiation Oncology Department, Hospital Clinic of Barcelona, Spain
b IDIBABS (Institut d’Investigacions Biomèdiques August Pi I Sunyer), Faculty of Medicine, University of Barcelona,
Spain
a r t i c l e i n f o
Article history:
Received 10 May 2018
Accepted 16 July 2018





a b s t r a c t
Locally advanced uterine cervical cancer continues to present a high number of pelvic
relapses. Intraoperative radiation therapy (IORT) allows a precise therapeutic intensifica-
tion in the surgical area in cases in which removal of the tumour recurrence is feasible. At
the same time, IORT excludes the radiosensitive organs from the field of irradiation. While
the first gynecological IORT took place in 1905, procedures have been limited over the years
and the series are retrospective, including few patients. At the same, time recurrences are
located at different pelvic areas. Both heterogeneity and the long recruiting time make it dif-
ficult to correctly interpret the published results. Despite this, we have reviewed the most
relevant publications. Some institutions indicated IORT as a boost on the surgical bed of
the excised tumor recurrence. In others, IORT permits an extra radiation dose after radical
surgery of the primary tumor, usually in stage IIB. Most studies conclude that the addi-
tion of IORT increases the local control but probably with little impact on survival. On the
other hand, there is a controversy in the indication of IORT in surgically resectable primary
tumours. No clear advantage over the usual scheme of chemoradiation and brachytherapy
has been detected. Randomized studies that allow a breakthrough in the conclusions are
highly unlikely to be performed in this area.
© 2018 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
1. Background
IORT (intraoperative radiation therapy) is a boosting technique
which delivers a single high dose fraction of radiation directly
to the resection bed during surgery. The goal is to selectively
irradiate anatomical areas that have been identified as high
risk of persistence of subclinical disease or even macroscopic
∗ Corresponding author at: Radiotherapy Department, Hospital Clinic, University of Barcelona, Villarroel St 170, 08036 Barcelona, Spain.
E-mail address: abiete@clinic.cat (A. Biete).
inextirpable residual disease. IORT permits, at the same time,
to protect or avoid surrounding organs or structures at risk
(OAR) because they are radiosensitive. This allows a good pro-
tection of pelvic organs like the bladder, rectum, bowel, etc.
and, consequently, a decrease in the incidence of enteritis,
rectitis or cystitis. IORT can be delivered using a dedicated lin-
https://doi.org/10.1016/j.rpor.2018.07.005
1507-1367/© 2018 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
590 reports of practical oncology and radiotherapy 2 3 ( 2 0 1 8 ) 589–594
Fig. 1 – Original picture of the first published IORT
treatment. The patient was irradiated to the distant
parametrial area and survive at least seven years. The
image is signed by Drs. C. Comas and A. Prio. Barcelona,
1905.
ear accelerator producing electron beams of different energies
and penetration degrees. X-rays sources delivering low-energy
radiation or high dose-rate brachytherapy sources can also
be conveniently used for IORT procedures in gynaecological
tumours, primary or recurrent.
In the Radiation Oncology literature, the first description
of an IORT procedure has been constantly attributed to Beck.1
Some years ago, an IORT treatment in the gynaecologic area
has been documented in Barcelona by Casas et al.2 Comas
and Prio3 reported the case of a 33 year old woman diagnosed
with a cervical squamous cell carcinoma treated by radical
surgery and intrapelvic roentgen therapy to the parametria.
The patient survived at least 6 years after the treatment was
completed (Fig. 1). Results were very limited for much of the
century, but with the introduction of megavoltage linear accel-
erators and later specifically designed units, reports of IORT
delivery procedures began to be published.
IORT has been used in the primary management, as well
as in the salvage setting, for many solid tumours in different
locations. It is estimated that the biological effect (RBE, rela-
tive biological efficacy) of this single large dose is equivalent
to up to 2–3 times the dose delivered with conventional exter-
nal beam radiotherapy. There probably exists an additional
benefit of diminishing the release of cell-growth stimulating
cytokines. This has been well reported by Belletti4 and later by
Zaleska et al.5
Two reviews have previously been published on IORT
in gynaecological tumours. The first one, from Backes and
Martin,6 comprises all gynaecologic malignancies, including
separate sections devoted to uterine primary tumours and
recurrent cervical cancer. A total number of 276 cases of cer-
vical cancer (primary and recurrent) were collected. The main
conclusion is that if the surgical margins are positive or close,
IORT appears to increase local control and has an acceptable
toxicity profile. The second one, recently published by Krengli
et al.,7 focuses on endometrial, cervical, renal, bladder and
prostate cancers. A total amount of 153 patients (primary and
recurrent cervical cancer) from 4 studies are analysed in detail.
They conclude as follows: In recurrent cervical cancer from
this studies, it emerged that the status of the margins is the
most important risk factor for treatment and the association
of IORT seems to improve the probability of local control. In
contrast, Krengli et al.7 do not recommend surgery and IORT
for primary tumours. They state: “The available data suggests
that this aggressive strategy is not advantageous in particular
for the risk of severe side effects and that concomitant radio-
chemotherapy alone should be considered the best treatment
strategy in this patient setting”.
In the present review we are going to try to separate the
results for primary tumours from those for recurrent cervical
tumours.
2. Intraoperative radiotherapy in cervical
locally advanced primary tumours
For many years, locally advanced uterine cervical tumours
have been treated by a chemoradiation approach, includ-
ing, if possible, brachytherapy. Although in more than half of
the patients the results are satisfactory, at least in one third
of them the tumour persists or a local or nodal recurrence
appears. For this reason, a therapeutic intensification asso-
ciating radical surgery and IORT has been tested. This novel
approach has been used mostly in FIGO stages IIB. (Table 1).
Martinez-Monge et al.8 reported in 2001 a series of 31
patients recruited from 1986 to 1999 presenting a locally
advanced but resectable cervix carcinoma. After chemora-
diation with cisplatin and 5 Fu and 45 Gy RT (Radiotherapy)
dose, surgery plus electron IORT was performed. The median
IORT dose was 12 Gy (range 10–25 Gy) focused on higher risk
areas (mainly pelvic walls). The mean field size was 6.5 cm
(range 5–12 Gy) and the beam energies 9 or 12 MeV, The authors
reported a 10 year 92.8% control rate “in field”. The 10-year
probability of pelvic control reached 78.6%. Toxicity presum-
ably attributable to IORT was detected in 14% of patients,
mainly transient pelvic pain or neuropathy in one case. They
concluded than IORT with electrons was a valuable radiation
boost technique in advanced but still resectable cervix carci-
noma.
Giorda et al.9 conducted a phase II study including
42 patients (stages IIB-IVA) between 2000 and 2007. They
were treated with external pelvic radiotherapy (50.4 Gy/28 fr)
and chemotherapy (cisplatin and 5FU weeks 1 and 5). No
brachytherapy was added. Surgery with radical hysterectomy
and pelvic lymphadenectomy was performed later (6–8 week).
During the surgery, IORT was delivered to the parametria,
pelvic sidewalls obturator fossa and iliac vessels. In case of
positive nodes or macroscopic residual tumour, IORT was
extended to treat the area. After chemoradiation, 83% of
patients underwent radical surgery and IORT. At pathologic
examination, 8/35 (23%) patients showed complete response,
but in 10/35 cases gross residual disease persisted. IORT was
delivered to the bilateral pelvic wall in 82% of patients, to the
mono-lateral pelvic wall in 11%, to the bilateral pelvic wall and
central pelvis in one case and to the bilateral pelvic wall and
para-aortic area also in one patient. The mean delivered dose
was 11 Gy (range from 10 to 15 Gy) and the mean diameter of
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Table 1 – Selected studies of the use of IORT (intraoperative radiotherapy) for gynecologic malignancies. OS: overall
survival; DFS: disease free survival; LC: local control.
Year Reference N Classification IORT median dose and range 5 y OS 5 y DFS 5 y LC
1995 Stelzer21 22 22 (14–27) Gy 43% – 48%
1996 Mahe15 70 Recurrent 18 (10–25) Gy 8% (3 y) – 30%
2001 Martinez-
Monge8
36 Recurrent 15 Gy 14% 16% 42%
31 Primary 12 Gy 67% 70% 79%
2002 Liu12 97 Primary (IIB) 19 (18–20) Gy 88% – –
2007 Tran18 17 Recurrent 11.5 (6–17.5) Gy 76% – 44%
2011 Giorda9 35 Primary 11 (10–15) Gy 49% 46% 89%
2013 Gao11 27 Primary 19 (18–20) Gy 78% 70% 100%






2014 Foley10 21 Recurrent 13.5 (10–22.5) Gy 69% 30% 59%
2014 Backes19 21 Recurrent 17.5 (10–20) Gy 30% – 59%
2014 Sole17 31 Recurrent 12.5 (10–15) Gy 42% 44% 65%
2016 Arians20 18 Recurrent 15 (10–18) Gy 6% – 44%
irradiation field was 6.3 cm (range from 5.7 to 8.3 cm). It is not
specified but we presume that IORT was administered using
an electron beam from a linear accelerator. Five-year disease-
free survival (DFS) was 46% and overall survival (OS) 49%.
Median time to recurrence was 22 months. Chemoradiation
was well tolerated but peri- and post-operative complications
occurred frequently. 3/15 deaths were due to septic pelvic
infections. There were no clearly related complications due
to IORT administration, but it is hard to discriminate from
other causes. Authors concluded that this treatment approach
seemed to be active in a subgroup of patients with patholog-
ical complete response to treatment or partial response with
residual tumour limited to the cervix. In our opinion, it is very
difficult in this study to make any kind of statement about the
role and efficacy of IORT.
It is also difficult to analyse it in the article by Foley et al.10
The authors presented a series of 32 patients treated with
IORT over 17 years (from 1994 to 2011). Among them, we iden-
tify 21 (65.6%) with a diagnosis of cervical cancer. It is not
clearly specified which cases are locally advanced primary
tumours or recurrent after previous surgery. An important
data is that in 84.4% of the patients, surgical resection margins
were microscopically positive and in 15.6% macroscopically
identifiable disease persisted. The mean IORT (electron beam)
dose was 13.5 Gy (range, 10–22.5) increasing the dose accord-
ing to the suspected or detected amount of local persistent
disease. The mean cone size used was 6.6 cm (range, 4–10 cm).
The irradiated areas were the pelvic side-wall in 59.4%, para-
aortic region and central pelvis in 21.8% and 18.8% patients,
respectively. The authors are not able to identify specific com-
plications due to the IORT procedure. They insist that the low
rate of neuropathy (only one case but grade III) is due to the
limit in IORT dose delivered to major nerves of 12.5 Gy. As a
general conclusion, Foley et al. suggest that IORT may benefit
patients with locally advanced or locally recurrent gynaeco-
logic cancers in whom complete resection of disease is feasible
at the time of IORT. Nevertheless, as usual, they insist on the
convenience to design and execute clinical trials permitting to
adequately assess this suggested benefit.
A more specific study was conducted by Gao et al.11
published in 2013. The authors reported the results of a ret-
rospective series of 27 women presenting an adenocarcinoma
of the uterine cervix in stage II. The rationale is based on the
worse prognosis of this histology in comparison to squamous
cell carcinoma. Between 1999 and 2002, 27 women with cervix
adenocarcinoma and FIGO stage IIB were enrolled and treated
as follows: they underwent weekly intracavitary brachyther-
apy (two insertions) total dose HDR 12–14 Gy point A. After a
break of 1–2 weeks, they underwent a simple hieterectomy and
selective lymphadenectomy. A dose of 18–20 Gy was delivered
intraoperatively using 12 MeV electron beam. A unique large
field of 10–12 cm in diameter was used, shifting out or protect-
ing the bladder, intestines, sigma and rectum. The portion of
the obturator nerve in the pelvis was partially shielded. Two
weeks after the IORT chemotherapy was implemented with
cisplatin and 5FU completing a total of 4–6 courses. The sur-
gical margins were positive in 2/27 cases and close in 6/27.
The mean follow-up time was 81 months and the 5-year OS
and DFS rates in all 27 patients were 77.8% and 70.4%, respec-
tively. Local relapse was detected in 2/27 patients (7.4%), but
none within the IORT field. Local control in field was 100%
whether or not the resection margins were positive or close.
IORT was well tolerated and the major complication observed
was peripheral neuropathy which two patients (7.4%) devel-
oped after 8 and 17 months. The authors concluded that IORT
was safe, feasible and appeared to confer a disease control
benefit to surgical resection in locally advanced cervix adeno-
carcinoma.
A similar therapeutic approach to that previously described
in adenocarcinoma was used some years before (2002) by a
Chinese work published by the same authors.12 IORT was
delivered in a series of 97 patients presenting cervical carci-
noma. The electron energy selected was 12 MeV and the dose
to the pelvic field ranged between 18 and 20 Gy. This sched-
ule was applied to stage IIB patients and the 5-year survival
rate achieved was 95%. Authors concluded that IORT provided
a new therapy method for cervical carcinoma stage IIB, espe-
cially for adenocarcinoma.
3. IORT in recurrent carcinoma of the
uterine cervix
Following the publication of two short series, Garton et al.13
and Kinney et al.,14 comprising 19 and 14 patients, the French
multicentre series was the largest trial published until 1996.15
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Between 1985 and 1993, 70 patients received IORT for pelvic
recurrence of cervical carcinoma in seven institutions. In most
of the patients (84%), the location of the pelvic failure was the
side wall and the central pelvis alone in 16%. A great vari-
ability in surgical procedures occurred, from biopsy alone to
pelvic exenteration. IORT was performed using 100 kV pho-
tons in 5 patients and electron beam in 65. Circular cones
with 10–20◦ bevels and a mean diameter of 73 cm were used
in most cases (95%). The mean follow-up after IORT was 15
months and at the time of the report, 78% of the patients
had died: 43% with local failure and 27% with local failure
and metastases. The overall survival (OS) at 1, 2 and 3 years
was 47, 17 and 8%, respectively, and the local control rate 21%.
Reported directly IORT-related toxicities were peripheral neu-
ropathy (5/70 cases) and ureteral stenosis (4/70). Conclusions
of the study are that IORT is feasible, but it cannot dramatically
improve prognosis.
Barney et al.16 published in 2013 a study conducted at the
Mayo Clinic reviewing the results of a retrospective series of
86 patients from 1983 to 2010. 13 (15%) were diagnosed of
locally advanced and 73 (85%) of locally recurrent cervix car-
cinoma. All patients in this study were treated using high
energy electrons from a linear accelerator. The median dose
prescribed to the 90% isodose was 15 Gy (range: 6.25–25 Gy)
and the most selected beam energies were 9 and 12 MeV.
The median cone size diameter was 7 cm (range: 5–15 cm).
Multivariate analysis revealed pelvic exenteration and peri-
operative IORT to be associated with improved local control.
Directly related IORT toxicity was peripheral neuropathy.
16 patients (19%) experienced some degree of it, but only
one grade 3. The authors concluded from this mixed study
that, if possible, IORT should be strongly considered, even
in previously irradiated patients, as the delivery of peri-
operative RT was associated with improved loco-regional
control.
Sole et al.17 published a study on 62 oligometastatic gynae-
cologic tumours. Among them, we identified 31 cervical
recurrent cancers. They were treated with surgery and elec-
tron IORT. The mean dose given was 12.5 Gy (range 10–15 Gy)
using a median energy of 12 MeV. Lucite circular applicators
ranged from 5 to 12 cm in diameter, bevelled if necessary.
Reported 5-year OS, DFS and Local control were 42%, 44%
and 65%, respectively. No IORT specifically related toxicity was
reported.
Tran et al.18 conducted in 2007 a study reporting the results
of IORT for recurrent gynaecologic malignancies. In this retro-
spective series, comprising 36 consecutive patients from 1986
to 2005, 17 (47%) were cervix tumours. IORT was delivered
using an orthovoltage unit. X-rays 200–250 kV, 0.57–2.45-mm
copper half value layer directly focused over the tumour bed.
Circular cones with diameters of 2.5–10 cm and bevels from 0◦
to 45◦ were used. Median dose was 11.5 Gy (6–17.5). Location
details for the cervix subgroup are not specifically reported.
The mean follow-up of the living patients was 50 months. The
5 year probability of local control was 45% and disease free sur-
vival (DFS) was 46% for the cervix cancer recurrence subgroup.
The local control rate was clearly superior in comparison to
21% reported by the French study, but one reasonable expla-
nation is the large difference in the rate of pelvic sidewall
location: 84% in the French study and 32% in the Stanford one.
The sidewall location is well known and accepted to have the
worst prognosis if compared to the central pelvis. They have a
low incidence of IORT-related complications attributed to the
policy of limiting the IORT dose to major nerves lower than
12.5 Gy and making every effort not to irradiate the ureters.
The main reported conclusion is that survival for pelvic recur-
rence of gynaecological cancer is poor, but IORT after surgery
seems to confer long-term local control in carefully selected
patients.
Backes et al.19 published in 2014 an article investigating if
the addition of IORT to pelvic exenteration for gynaecologic
cancer recurrences improved survival. 32 patients were iden-
tified in this retrospective study. The majority of them had
recurrent cervical cancer (21, 66%). The IORT doses ranged
from 10 to 20 Gy (median 17.5 Gy). Electron energies ranged
from 6 to 12 MeV and the dose was prescribed to the 90%
isodose line. The main difficulty regarding the results of this
series was that only 66% received IORT during the surgery
and neither the amount of cervical tumours nor the specific
local control rates achieved were reported. The broad con-
clusion is that IORT fails to change survival and recurrence
outcomes. But, and it is very important, authors report that
patients with clinical indications at the time of pelvic exen-
teration have a worse prognosis compared to those who do
not require IORT. Then, it is reasonable to conclude that, as
the local recurrence rate is similar in the two subgroups (36
and 31%), IORT contributes significantly to the rise in local
control.
At our best knowledge, the most recent published article
is a German one from Heidelberg (Arians et al.).20 A series
of 36 patients with recurrent gynaecological malignancies,
including 18 cervical cancers, were enrolled between 2002
and 2014. They underwent surgical resection combined with
IORT. The median radiation dose was 15 Gy (range 10–18 Gy)
with a median electron energy of 8 MeV (range 6–15 MeV) pre-
scribed to the 90% isodose. IORT dose was usually restricted
to 10–12 Gy, if major nerves had to be included in the radia-
tion field. The median follow-up was 14 months. For patients
with cervical cancer, 5-year OS was 6.4%, quite different from
endometrial recurrences (50%). Local pelvic progression was
documented in 10 of 18 cervix recurrences. IORT attributed
toxicity consists in neuropathy in 11% of patients. No ureter
stenosis was reported. The authors conclude that a radical
procedure of resection combined with IORT seems to be a cura-
tive option for patients with recurrent endometrial carcinoma
with 5-year survival rates of 50%. For patients with cervical
or vulvar cancer this treatment should be considered a rather
than palliative one.
Our institutional experience is short. Our IORT program
started in 2013 with a mobile electron linear accelerator (LIAC)
installed in a specifically designed operation room. Treat-
ment objectives are mainly focused on conservative breast
cancer but, until now, 7 patients were treated with surgery
and IORT for recurrent cervix cancer. The median follow
up is short, 13 months, but at the present 5 of 7 patients
are living without recurrence and in complete remission.
No neuropathy or ureteral toxicity have been detected until
now.
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4. Conclusions
The total number of cervix cancers collected from the referred
studies is 512, of which 203 (39.6%) are primary tumours (most
of them stage IIB) and 287 (60.4%) recurrent. An additional
group of 22 is not clearly specified. In several publications it
has been difficult to identify cervical tumours data from other
locations and diagnoses, like the endometrium or vulva. We
must recognize and advert about possible errors because of
the difficulties explained above. The collected data comprises
a long publishing period: 20 years (1996–2016). The median
number of cervix patients per article is 42.6 and the median
enrolment time per article is 14 (range 7–27). The median
yearly collection rate is as low as 2.8 (range 0.9–5.1). From these
data, we should conclude that we face a relatively small pop-
ulation, collected along a long time and in the French study
(15) from multiple centres (7 institutions).
Additionally, there are other parameters of heterogeneity.
Some of them are as follows: recurrence sites of different prog-
nosis, like the pelvic walls or central pelvic recurrences, free
margins on resection, tumour initial and residual burden, high
level of heterogeneity according to different techniques, ener-
gies, fields, doses, etc. What is more, the conclusions of the
referred studies are frequently different. Obviously, it is not
easy to demonstrate the efficacy and the benefit of IORT in ret-
rospective limited series. IORT is a radiation boost in a surgical
procedure. In well designed aleatorized prospective studies
it is frequently difficult to demonstrate the degree of local
control benefit of postoperative radiotherapy. It is particularly
difficult in IORT because it is necessarily associated with dif-
ferent degrees of radicality in surgery, from local resection to
pelvic exenteration.
But most of the referred manuscripts agree that adding
IORT to a surgical resection is a right strategy rising the
local control rate. There are more doubts about the influ-
ence over the survival and probably there is a little impact.
But in cervix cancer local control has a strong influence on
the quality of life. We must keep in mind that half of the
mortality in cervix cancer is due to a non controlled pelvic
disease.
By contrast, the therapeutic approach in primary tumours,
including surgery and IORT, is strongly debated. It seems,
there is no clear advantage over the standard well established
approach, including chemoradiotherapy and brachytherapy.
But there is some agreement that, if surgery is a therapeu-
tic option, IORT is an effective tool adding extra security and
rising the local control rate.
Finally, we must point out the difficulty and the low
probability to design and realize aleatorized prospective tri-
als. Low accrual of a sufficient number of patients in a
reasonable period of time and the heterogeneity of recur-
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